Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method

Table 3 The mean and median patient WTP

	PFS WTP	PFS-QoL WTP	PPS WTP	PPS-QoL WTP	WTP for ‘standard QALY’
Average value	157,443	147,991	176,381	158,137	168,376
WTP/GDP	1.94	1.83	2.18	1.95	2.08
Average after trimming 5%	128,103	133,949	144,731	143,871	148,443
WTP/GDP	1.58	1.65	1.79	1.78	1.83
Median value	66,667	66,667	86,667	80,000	106,667
WTP/GDP	0.82	0.82	1.07	0.99	1.32
Preference by Nonparametric tests	PFS WTP
	0.859	PFS-QoL WTP
	0.31	0.316	PPS WTP
	0.392	0.945	0.592	PPS-QoL WTP
Preference by Nonparametric tests	PFS vs PPS		Life prolong vs QoL increase
	0.522		0.953

ISSN: 1478-7547